Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig monotherapy in recurrent or metastatic head and neck squamous cell carcinoma
CTR20243570Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of volrustomig in head and neck squamous cell carcinoma (HNSCC), sponsored by AstraZeneca. Started Nov 2024; status: active.
02
Drugs
volrustomig
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20243570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243570.